Objective:To investigate the effects of Gongliuxiao Capsule on inflammatory factors, tumor markers, sex hormones and vascular endothelial function in patients with uterine fibroids. Methods:130 patients with uterine f...Objective:To investigate the effects of Gongliuxiao Capsule on inflammatory factors, tumor markers, sex hormones and vascular endothelial function in patients with uterine fibroids. Methods:130 patients with uterine fibroids admitted to our hospital from October 2015 to March 2017 were enrolled. According to the treatment, they were divided into single treatment group and combined medication group, with 65 cases in each group. The changes of inflammatory factors, tumor markers, sex hormones and vascular endothelial function were compared before and after treatment in the two groups.Results: There were no significant differences in the levels of sex hormones, inflammatory factors, tumor markers and vascular endothelial function between the two groups (P>0.05). The levels of sex hormones E2, P, FSH and LH, the levels of inflammatory factors TNF-α, MMP-9 and IGF-1, tumor markers CA125, CA19-9 and vascular endothelial function VEGF and b-FGF were significantly lower in the two groups (P<0.05). The levels of E2, P, FSH and LH in the combined drug groupswere (154.12±16.20) pmol/L, (9.12±1.02) μg/L, (13.84±1.42) U/L and (12.77±1.36) U/L, respectively,which were significantly lower than the single drug group level (P<0.05). The levels of CA125 and CA19-9 in the combined drug group were (27.89±2.88) U/mL and (28.09±3.04) U/mL, respectively, which were significantly lower than the single drug group (P<0.05). The levels of TNF-α, MMP-9 and IGF-1 in the combined drug group were (24.16±2.63) ng/L, (159.22±16.82) μg/L and (69.75±7.09) μg/L, respectively, which were significantly lower than the single drug group(P<0.05). The levels of VEGF and b-FGF in the combination group were (138.29±14.32) μg/L and (98.59±10.02) μg/L, respectively, which were significantly lower than the single drug group (P<0.05).Conclusion:Mifepristone combined with Gongliuxiao Capsule can alleviate endocrine disorders, relieve inflammatory stress response and improve vascular endothelial function in patients with uterine fibroids. It is worthy of clinical application.展开更多
目的:采用HPLC法同时检测宫瘤消胶囊(GLX)中13种成分含量,并联合化学计量学及灰色关联度分析(GRA)对GLX质量进行综合评价。方法:以Dikmatech Diamonsil Plus C18为色谱柱,乙腈-0.1%磷酸为流动相,同时测定GLX中党参炔苷、紫丁香苷、鸡矢...目的:采用HPLC法同时检测宫瘤消胶囊(GLX)中13种成分含量,并联合化学计量学及灰色关联度分析(GRA)对GLX质量进行综合评价。方法:以Dikmatech Diamonsil Plus C18为色谱柱,乙腈-0.1%磷酸为流动相,同时测定GLX中党参炔苷、紫丁香苷、鸡矢藤次苷甲酯、车叶草苷酸、车叶草苷、氧化芍药苷、芍药苷、丹皮酚、香附烯酮、圆柚酮、α-香附酮、莪术二酮和莪术醇的含量。采用化学计量学挖掘影响GLX产品质量的主要标记物。基于灰色关联度法分析不同批次GLX各指标成分数据,以相对关联度为测度,对GLX综合质量进行评价。结果:13种成分在各自范围内线性关系良好(r>0.999),平均加样回收率(n=9)在96.81%~100.19%之间(RSD<2.0%)。化学计量学分析显示莪术二酮、香附烯酮、丹皮酚、车叶草苷、党参炔苷、鸡矢藤次苷甲酯、芍药苷和氧化芍药苷是影响GLX产品质量的主要潜在标志物。灰色关联度分析相对关联度0.3302~0.6068,GLX存在一定批间差异。结论:所建立的HPLC多组分定量联合化学计量学及灰色关联度分析方法,操作便捷、结果准确、全面客观,可用于GLX质量的综合评价,为该制剂质量控制提供参考。展开更多
目的筛选宫瘤消胶囊的主要活性成分,探索其治疗子宫肌瘤的主要作用机制。方法利用TCMSP数据库及文献收集查找宫瘤消胶囊主要化学成分;通过ADME生物代谢参数筛选主要活性成分;借助TCMSP、STITCH数据库进行靶点检索;使用TTD、GAD、pharmGk...目的筛选宫瘤消胶囊的主要活性成分,探索其治疗子宫肌瘤的主要作用机制。方法利用TCMSP数据库及文献收集查找宫瘤消胶囊主要化学成分;通过ADME生物代谢参数筛选主要活性成分;借助TCMSP、STITCH数据库进行靶点检索;使用TTD、GAD、pharmGkb、Opentarget、DiGSeE在线文本挖掘工具及查阅文献,搜集子宫肌瘤相关靶点;通过Cytoscape软件构建关键成分靶点蛋白相互作用网络,筛选核心靶点;利用Accelrys Discovery Studio 2.5软件进行活性分子与核心靶点对接;利用STRTING数据库分析靶点GO功能富集;运用Cytoscape软件ClueGo插件分析Pathway通路富集。结果筛选宫瘤消胶囊72个潜在活性成分,其对应的靶点171个,子宫肌瘤靶点50个,成分靶点蛋白相互作用核心靶点123个,分子对接表明宫瘤消胶囊潜在活性成分较好地结合到核心靶蛋白的活性口袋中,富集出的核心靶点可靠。GO功能富集分析表明宫瘤消胶囊抗子宫肌瘤主要与细胞代谢、生物过程调节、核染色体、激素受体、转录因子等有关;网络特征富集分析22条生物通路。结论宫瘤消胶囊主要成分核心靶点主要分布于子宫肌瘤密切相关的3条通路中,瘦素、催乳素、Rac1/Pak1/P38/MMP-2信号通路,通过下调信号通路的活性,从而抑制子宫平滑肌瘤细胞的生长或促进细胞凋亡发挥作用。展开更多
文摘Objective:To investigate the effects of Gongliuxiao Capsule on inflammatory factors, tumor markers, sex hormones and vascular endothelial function in patients with uterine fibroids. Methods:130 patients with uterine fibroids admitted to our hospital from October 2015 to March 2017 were enrolled. According to the treatment, they were divided into single treatment group and combined medication group, with 65 cases in each group. The changes of inflammatory factors, tumor markers, sex hormones and vascular endothelial function were compared before and after treatment in the two groups.Results: There were no significant differences in the levels of sex hormones, inflammatory factors, tumor markers and vascular endothelial function between the two groups (P>0.05). The levels of sex hormones E2, P, FSH and LH, the levels of inflammatory factors TNF-α, MMP-9 and IGF-1, tumor markers CA125, CA19-9 and vascular endothelial function VEGF and b-FGF were significantly lower in the two groups (P<0.05). The levels of E2, P, FSH and LH in the combined drug groupswere (154.12±16.20) pmol/L, (9.12±1.02) μg/L, (13.84±1.42) U/L and (12.77±1.36) U/L, respectively,which were significantly lower than the single drug group level (P<0.05). The levels of CA125 and CA19-9 in the combined drug group were (27.89±2.88) U/mL and (28.09±3.04) U/mL, respectively, which were significantly lower than the single drug group (P<0.05). The levels of TNF-α, MMP-9 and IGF-1 in the combined drug group were (24.16±2.63) ng/L, (159.22±16.82) μg/L and (69.75±7.09) μg/L, respectively, which were significantly lower than the single drug group(P<0.05). The levels of VEGF and b-FGF in the combination group were (138.29±14.32) μg/L and (98.59±10.02) μg/L, respectively, which were significantly lower than the single drug group (P<0.05).Conclusion:Mifepristone combined with Gongliuxiao Capsule can alleviate endocrine disorders, relieve inflammatory stress response and improve vascular endothelial function in patients with uterine fibroids. It is worthy of clinical application.
文摘目的:采用HPLC法同时检测宫瘤消胶囊(GLX)中13种成分含量,并联合化学计量学及灰色关联度分析(GRA)对GLX质量进行综合评价。方法:以Dikmatech Diamonsil Plus C18为色谱柱,乙腈-0.1%磷酸为流动相,同时测定GLX中党参炔苷、紫丁香苷、鸡矢藤次苷甲酯、车叶草苷酸、车叶草苷、氧化芍药苷、芍药苷、丹皮酚、香附烯酮、圆柚酮、α-香附酮、莪术二酮和莪术醇的含量。采用化学计量学挖掘影响GLX产品质量的主要标记物。基于灰色关联度法分析不同批次GLX各指标成分数据,以相对关联度为测度,对GLX综合质量进行评价。结果:13种成分在各自范围内线性关系良好(r>0.999),平均加样回收率(n=9)在96.81%~100.19%之间(RSD<2.0%)。化学计量学分析显示莪术二酮、香附烯酮、丹皮酚、车叶草苷、党参炔苷、鸡矢藤次苷甲酯、芍药苷和氧化芍药苷是影响GLX产品质量的主要潜在标志物。灰色关联度分析相对关联度0.3302~0.6068,GLX存在一定批间差异。结论:所建立的HPLC多组分定量联合化学计量学及灰色关联度分析方法,操作便捷、结果准确、全面客观,可用于GLX质量的综合评价,为该制剂质量控制提供参考。
文摘目的筛选宫瘤消胶囊的主要活性成分,探索其治疗子宫肌瘤的主要作用机制。方法利用TCMSP数据库及文献收集查找宫瘤消胶囊主要化学成分;通过ADME生物代谢参数筛选主要活性成分;借助TCMSP、STITCH数据库进行靶点检索;使用TTD、GAD、pharmGkb、Opentarget、DiGSeE在线文本挖掘工具及查阅文献,搜集子宫肌瘤相关靶点;通过Cytoscape软件构建关键成分靶点蛋白相互作用网络,筛选核心靶点;利用Accelrys Discovery Studio 2.5软件进行活性分子与核心靶点对接;利用STRTING数据库分析靶点GO功能富集;运用Cytoscape软件ClueGo插件分析Pathway通路富集。结果筛选宫瘤消胶囊72个潜在活性成分,其对应的靶点171个,子宫肌瘤靶点50个,成分靶点蛋白相互作用核心靶点123个,分子对接表明宫瘤消胶囊潜在活性成分较好地结合到核心靶蛋白的活性口袋中,富集出的核心靶点可靠。GO功能富集分析表明宫瘤消胶囊抗子宫肌瘤主要与细胞代谢、生物过程调节、核染色体、激素受体、转录因子等有关;网络特征富集分析22条生物通路。结论宫瘤消胶囊主要成分核心靶点主要分布于子宫肌瘤密切相关的3条通路中,瘦素、催乳素、Rac1/Pak1/P38/MMP-2信号通路,通过下调信号通路的活性,从而抑制子宫平滑肌瘤细胞的生长或促进细胞凋亡发挥作用。
